AOD 9604 Research Benefits Overview
AOD 9604 is a modified fragment of human growth hormone (amino acids 176-191) that retains the lipolytic (fat metabolizing) activity of full-length hGH without its growth-promoting or diabetogenic effects. This selective activity profile has made AOD 9604 a unique tool in metabolic and obesity research.
Fat Metabolism Research Benefits
AOD 9604’s primary research benefit is its targeted effect on adipose tissue:
- Stimulates lipolysis (fat breakdown) in adipose tissue
- Inhibits lipogenesis (new fat formation)
- Acts through beta-3 adrenergic receptor pathway
- Does not affect IGF-1 levels, blood glucose, or growth parameters
- No antibody formation observed in long-term studies
Selective Activity Profile
The key advantage of AOD 9604 in research is what it doesn’t do. Unlike full-length growth hormone, AOD 9604 does not:
- Stimulate IGF-1 production
- Cause insulin resistance or glucose intolerance
- Promote cell proliferation
- Affect bone or organ growth
This selectivity allows researchers to study fat metabolism pathways in isolation from other GH effects.
Clinical Trial Evidence
AOD 9604 progressed through Phase 2 and 3 clinical trials, providing a robust body of human safety and efficacy data. The trials demonstrated a favorable safety profile with metabolic improvements in adipose tissue parameters.
Comparison with Other Metabolic Compounds
AOD 9604 operates through different mechanisms than GLP-1 agonists like semaglutide (appetite/satiety pathway) or mitochondrial peptides like MOTS-C (AMPK/energy sensing). See our AOD 9604 vs Semaglutide comparison.
For dosing, see AOD 9604 dosage guide. Browse our full catalog.
For research and educational purposes only. AOD 9604 is a research compound. Visit COAs.